(NASDAQ: LPTX) Leap Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Leap Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast LPTX's revenue for 2026 to be $229,907,382, with the lowest LPTX revenue forecast at $229,907,382, and the highest LPTX revenue forecast at $229,907,382. On average, 1 Wall Street analysts forecast LPTX's revenue for 2027 to be $1,107,387,223, with the lowest LPTX revenue forecast at $1,107,387,223, and the highest LPTX revenue forecast at $1,107,387,223.
In 2028, LPTX is forecast to generate $1,067,574,928 in revenue, with the lowest revenue forecast at $1,067,574,928 and the highest revenue forecast at $1,067,574,928.